Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2013

View Archived Issues

Cancer vaccine K562/GM-CSF evaluated in patients with myelodysplastic syndrome

Sotatercept well tolerated in patients with beta-thalassemia

Development of a novel microfluidic biosensor for real-time in vivo monitoring of drug concentration

Amgen reports topline results from 52-week phase III DESCARTES study

Vertex Pharmaceuticals reports data from study of ivacaftor in patients with R117H mutation

MicuRx begins global development program for lead compound

NeuroPhage awarded second grant from Michael J. Fox Foundation

NewLink Genetics begins phase I trial of HyperAcute Renal

Sorrento Therapeutics completes Concortis Biosystems acquisition

Ares Trading prepares novel Abeta inhibitors for neurodegenerative disorders

Jazz Pharmaceuticals to acquire Gentium

OncoTherapy Science stops phase III study of C-01 for pancreatic cancer

Ultragenyx reports phase II data for UX-001 in hereditary inclusion body myopathy

Orion signs agreement with Janssen Pharmaceuticals in Alzheimer's disease

NovaBiotics begins development of inhaled Lynovex for cystic fibrosis

FDA delays action on Vascepa sNDA

FDA awards QIDP and fast track designations to TaiGen's nemonoxacin

Bayer plans to acquire Algeta

Novel humanized antibodies targeting human Trk-A disclosed by Glenmark Pharmaceuticals

Daiichi Sankyo reports novel ROS and Trk inhibitors for cancer

WARF prepares new VDR ligands for bone and other disorders

Arrowhead Research presents first-in-human results for ARC-520

EMA accepts tolvaptan MAA for ADPKD

Envarsus granted orphan drug status by the FDA

FDA issues CRL for Actavis' progestin-only transdermal contraceptive patch

CHMP gives positive opinion on subcutaneous tocilizumab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...